Idorsia Ltd

Headquarters: Allschwil, Switzerland

CEO: Mr. Jean-Paul Clozel M.D.

show_chart SIX: IDIA +6.90%

Market Cap

CHF2.50 Billion

CHF as of Jan. 1, 2023

US$2.70 Billion

history Market Cap History

Idorsia Ltd market capitalization over time

Evolution of Idorsia Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Idorsia Ltd

Detailed Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Stocks & Indices

Idorsia Ltd has the following listings and related stock indices.

Stock: SIX: IDIA



Hegenheimermattweg 91

Allschwil, 4123


Phone: 41 58 844 00 00